Post by Opkotunist on Sept 27, 2016 15:16:04 GMT
I read with great interest in Nature Medicine the dramatic impact, these new class of drugs called ACC inhibitors have on cancers : Tumors shrinking as much as 80%. While still a ways off until they find their way in the clinics, their action of fat synthesis inhibition and the importance cancer cells rely made me think of Oxyntomodulin's role in inhibiting fat synthesis. It has long been shown the close link between obesity and cancer, sure enough, oxyntomodulin through its glucagon mediated pathways may also inhibit ACC. So Oxyntomodulin may not only treat pbesity one day, but if this science plays out, could also be an oncology drug has well. It would be nice if Opko could buy Nimbus Therapeutics ACC inhibitors business but Gilead Sciences bought it last year for 1.2 B.